UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) |
3 Months Ended | 9 Months Ended | |||||
|---|---|---|---|---|---|---|---|
Jun. 30, 2017 |
Jun. 30, 2016 |
Jun. 30, 2017 |
Jun. 30, 2016 |
||||
| REVENUES | |||||||
| Neurometric Services | $ 40,400 | $ 21,100 | $ 94,500 | $ 66,500 | |||
| OPERATING EXPENSES | |||||||
| Cost of neurometric services revenue | 16,200 | 1,500 | 23,700 | 4,100 | |||
| Research | 40,600 | 17,500 | 101,500 | 62,800 | |||
| Product development | 278,900 | 224,900 | 867,000 | 531,200 | |||
| Sales and marketing | 292,100 | 158,100 | 589,600 | 414,200 | |||
| General and administrative | 966,800 | 428,300 | 2,922,800 | 1,178,100 | |||
| Total operating expenses | 1,594,600 | 830,300 | 4,504,600 | 2,190,400 | |||
| OPERATING LOSS | (1,554,200) | (809,200) | (4,410,100) | (2,123,900) | |||
| OTHER INCOME (EXPENSE): | |||||||
| Interest expense, net | (1,900) | (487,900) | (5,800) | (1,227,700) | |||
| Loss on extinguishment of debt | (2,337,400) | [1] | |||||
| Finance fees | (20,000) | (20,000) | |||||
| Gain on derivative liabilities | 237,700 | 1,035,900 | |||||
| Legal settlement accrual | (275,000) | (275,000) | [1] | ||||
| Total other income (expense) | (1,900) | (545,200) | (5,800) | (2,824,200) | |||
| LOSS BEFORE PROVISION FOR INCOME TAXES | (1,556,100) | (1,354,400) | (4,415,900) | (4,948,100) | |||
| Income taxes | 16,300 | 48,700 | 300 | ||||
| NET LOSS | $ (1,572,400) | $ (1,354,400) | $ (4,464,600) | $ (4,948,400) | [1] | ||
| BASIC AND DILUTED LOSS PER SHARE: | |||||||
| From continuing operations (in dollars per share) | $ (0.62) | $ (2.53) | $ (1.91) | $ (9.5) | |||
| WEIGHTED AVERAGE SHARES OUTSTANDING: | |||||||
| Basic and Diluted (in shares) | 2,535,394 | 535,805 | 2,336,283 | 520,412 | |||
| |||||||
| X | ||||||||||
- Definition Refers to the amount related to finance fees incurred during the period. No definition available.
|
| X | ||||||||||
- Definition The aggregate costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique. No definition available.
|
| X | ||||||||||
- Definition The expense related to research activities incurred by the entity during the reporting period. No definition available.
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in the fair value of derivatives recognized in the income statement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares. No definition available.
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The net amount of nonoperating interest income (expense). No definition available.
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- Definition The amount of cash paid for the settlement of litigation or for other legal issues during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
- Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|